首页> 外文期刊>Pathology Research and Practice >Immunohistochemical COX-2 overexpression correlates with HER-2eu overexpression in invasive breast carcinomas: a pilot study.
【24h】

Immunohistochemical COX-2 overexpression correlates with HER-2eu overexpression in invasive breast carcinomas: a pilot study.

机译:浸润性乳腺癌中免疫组化COX-2的过度表达与HER-2 / neu的过度表达相关:一项初步研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Cyclooxygenase-2 (COX-2) is a prostaglandin synthase that catalyzes the synthesis of prostaglandin G2 and H2. It has been shown that COX-2 plays an important role in tumorigenesis of different tumor types and it is thought to take part in breast carcinogenesis. In the present study, we aimed to investigate the relationship of immunohistochemical COX-2 expression with clinicopathological parameters, including HER-2eu overexpression in invasive breast carcinoma (IBC). Our study population comprised 10 normal breasts, 25 ductal carcinomas in situ (DCIS), and 51 invasive breast carcinomas. Immunohistochemical overexpressions of COX-2 and HER-2eu were investigated in sections of formalin-fixed, paraffin-embedded blocks by 3 observers. In normal breast, DCIS and IBC, the COX-2 overexpression rate was 0%, 84%, and 58.8%, respectively. In IBC, COX-2 overexpression had a significant relationship with HER-2eu overexpression (p=0.026) and a high histological grade (p=0.026). COX-2 expression in both DCIS (n=25) and IBC (n=51) was significantly higher than in normal breast tissue (p<0.0001). In addition, the COX-2 expression rate was significantly higher in DCIS than in IBC (p=0.042). Our results indicated that COX-2 overexpression correlates with aggressive phenotypic features, such as HER-2eu overexpression and high histological grade in IBC. Increased expression of COX-2 in both DCIS and IBC in comparison to normal breast could indicate a role in breast carcinogenesis. COX-2 overexpression may provide a clinically useful biomarker for estimating tumor aggressiveness.
机译:环氧合酶2(COX-2)是一种前列腺素合酶,可催化前列腺素G2和H2的合成。已经表明,COX-2在不同肿瘤类型的肿瘤发生中起重要作用,并且据认为参与了乳腺癌的致癌作用。在本研究中,我们旨在研究免疫组化COX-2表达与浸润性乳腺癌(IBC)中包括HER-2 / neu过表达在内的临床病理参数的关系。我们的研究人群包括10例正常乳房,25例原位导管癌和51例浸润性乳腺癌。由3名观察者在福尔马林固定,石蜡包埋的切片中研究了COX-2和HER-2 / neu的免疫组织化学过表达。在正常乳腺,DCIS和IBC中,COX-2过表达率分别为0%,84%和58.8%。在IBC中,COX-2过表达与HER-2 / neu过表达(p = 0.026)和组织学评分高(p = 0.026)有显着关系。 DCIS(n = 25)和IBC(n = 51)的COX-2表达均显着高于正常乳腺组织(p <0.0001)。此外,DCIS中的COX-2表达率显着高于IBC(p = 0.042)。我们的结果表明,COX-2的过表达与侵袭性的表型特征相关,如HER-2 / neu的过表达和IBC的高组织学分级。与正常乳腺相比,DCIS和IBC中COX-2的表达增加可能表明其在乳癌发生中起作用。 COX-2的过表达可能为评估肿瘤侵袭性提供临床上有用的生物标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号